methoxy polyethylene glycol-ep
ApprovedSmall molecule
Rochemethoxy polyethylene glycol-ep is one of 158 small molecule programs targeting Diabetic Nephropathy. It is currently in Approved.
5
Indications
65
Total Trials
0
Active Trials
157
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1methoxy polyethylene glycol-ep
RocheApproved
PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anemia36 trials
Show 33 more trials
Chronic Kidney Disease19 trials
Show 16 more trials
Non-Small Cell Lung Cancer2 trials
Dialysis Patients2 trials
5 more indications
Kidney Transplant1 trial
Peritoneal Dialysis1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]